Complex treatment of retinal veins occlusion

Cover Page

Cite item

Full Text

Abstract

Aim. To assess the efficacy of complex treatment of retinal veins occlusion with anti-angiogenic - ranibizumab, and laser retinal photocoagulation. Methods. 36 patients (36 eyes) with occlusion of central retinal vein and its branches were included. Patients with central retinal vein occlusion (n=17) were included in the first group, patients with retinal vein branch occlusion (n=19) were included in the second group. All the patients underwent visual acuity testing, ocular tonometry, ophthalmoscopy, biomicroscopy, spectral optical coherence tomography, intravenous fluorescein angiography at the baseline, 1 and 3 months after treatment. Treatment included intravitreal ranibizumab injection (0.5 mg) and laser retinal photocoagulation 1 month after intravitreal injection. Results. In 94.4% of cases good treatment effect was observed. Visual acuity improved from 0.06±0.03 at baseline to 0.22±0.08 (p <0.05) at the end of treatment in the first group and from 0.31±0.06 to 0.64±0.05 (p <0.05) in the second group. Central retinal thickness reduced from 752.2±98.4 μm to 309.21±45.57 μm (p <0.05) in the first and from 689.12±64.08 μm to 235.37±46.07 μm (p <0.05) in the second group. Conclusion. The results indicate high effectiveness of suggested complex treatment of retinal vein occlusion with anti-angiogenic - ranibizumab and laser retinal photocoagulation.

About the authors

E A Abdulaeva

Kazan State Medical Academy, Kazan, Russia

Email: abd@inbox.ru

A N Amirov

Kazan State Medical Academy, Kazan, Russia

E P Beriya-Dzhorgzhikiya

Republican clinical ophthalmological hospital, Kazan, Russia

A N Korobitsyn

Republican clinical ophthalmological hospital, Kazan, Russia

References

  1. Тульцева С.Н., Астахов Ю.С. Окклюзии вен сетчатки. - СПб.: Издательство Н-Л, 2010. - 112 с.
  2. Brown D.M., Campochiaro P.A., Singh R.P. et al. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study // Ophthalmology. - 2010. - Vol. 117. - P. 1124-1133.
  3. Campochiaro P.A., Heier J.S., Feiner L. et al. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study // Ophthalmology. - 2010. - Vol. 117. - P. 1102-1112.
  4. Capua M., Coppola A., Albisinni R. et al. Cardiovascular risk factors and outcome in patients with retinal vein occlusion // J. of Thromb. Thrombolysis. - 2010. - Vol. 30. - P. 16-22.
  5. Christoffersen N.L., Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion // Ophthalmology. - 1999. - Vol. 106. - P. 2054-2062.
  6. Coscasa G., Loewensteinb A., Augustinc А. et al. Management of retinal vein occlusion // Ophthalmology. - 2011. - Vol. 226. - P. 4-28.
  7. Cugati S., Wang J.J., Rochtchina E., Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study // Arch. Ophthalm. - 2006. - Vol. 124. - P. 726-732.
  8. Duker J.S., Brown G.C. Anterior location of the crossing artery in branch retinal vein obstruction // Arch. Ophthalm. - 1989. - Vol. 107. - P. 998-1000.
  9. Haymore J.G., Mejico L.J. Retinal vascular occlusion syndromes // Int. Ophthalmol. Clin. - 2009. - Vol. 49. - P. 63-79.
  10. Janssen M.C., den Heijer M., Cruysberg J.R. et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors // J. of Thromb. Haemost. - 2005. - Vol. 93. - P. 1021-1026.
  11. L’Esperance F.A. Ophalmic lasers photocoagulation, photoradiation, and surgery. - Toronto, London: Mosby Company, St. Louis, 1983. - 606 p.
  12. Rogers S.L., McIntosh R.L., Lim L. et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review // Ophthalmology. - 2010. - Vol. 117. - P. 1094-1101.

© 2012 Abdulaeva E.A., Amirov A.N., Beriya-Dzhorgzhikiya E.P., Korobitsyn A.N.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies